Cerense^SM

Overcoming the challenges of CNS drug delivery and assessment

Cerense^SM is a unique integrated solution designed to substantially improve the development success of potential CNS medicines that normally exhibit poor permeation of the BBB. By bringing together the strengths of Genzyme Pharmaceuticals and Pharmidex, Cerense overcomes the challenges of CNS drug delivery and assessment.

Genzyme Pharmaceuticals’ proprietary formulation technology opens the BBB and delivers unmodified drug compounds into the brain, avoiding the disadvantages of direct application of poorly brain penetrant compounds into the brain. This overcomes the first major obstacle.

Pharmidex is the only company offering direct assessment of brain penetrability and free concentration of compounds in ECF using microdialysis. This is underpinned by the integration of neuroscience, DMPK and CNS drug discovery expertise. The knowledge delivered by their studies overcomes the second major obstacle.

CNS drug delivery studies, conducted in state-of-the-art facilities by the Pharmidex team, provides a comprehensive assessment of the concentration and duration of the test compound in brain ECF. The design of in-life experiments, coupled with clear and consistent data, will facilitate sound decision making for CNS drug discovery projects. Drug candidates can subsequently be developed and administered using Genzyme’s novel and proprietary CNS delivery technology.

Cerense, thus, provides a unique product development platform designed to unlock the potential of compounds constrained by poor BBB penetration, as well as opens new avenues for the creation of CNS medicines. Companies that overcome the twin obstacles, and develop CNS medicines with a good therapeutic ratio, stand to dominate this fastest growing sector of the pharmaceuticals market.

Terms and Conditions of Use | Privacy Policy | © 2002-2008 Genzyme Corporation. All rights reserved.